Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
|
|
Integrated Regional Information Networks - July 19, 2000
Speaking at a media briefing in Pretoria, the minister said that the Intrapartum Nevirapine Trials (SAINT) results presented formally at the international AIDS conference in Durban last week had left many questions, mainly around the impact of breastfeeding and the possibility of drug resistance.
Last week Boehringer Ingelheim, an international pharmaceutical company said at the Durban conference that its clinical trial had shown nevirapine was effective in reducing MTCT of HIV/AIDS. It also said that it would offer the drug free to the South African ministry of health. At the time the ministry said it was considering the offer once "certain factors had been considered". Nevrapine is not yet registered in South Africa.
The minister said that she was concerned that the media and the South African public were "pushing government in a corner, forcing us to provide nevirapine, when even the scientists themselves still have unanswered questions about the drug".
She said she hoped that a government meeting with scientists on 12-13 August would bring "clarity to these questions". She said that it was not possible to say when the department would issue nevirapine to pregnant HIV positive women in South Africa. Statistics released at the Durban conference showed that South Africa had one of the largest HIV/AIDS infection rates in the world.
000719
IR000704
Copyright © 2000 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .